Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1NET 1Gastrointestinal 1Endocrine 1

Conditions

Neuroendocrine Tumors 1Neoplasms 1Multiple Myeloma 1Gastrointestinal Neoplasms 1

Interventions

Everolimus 6Sunitinib 4Octreotide 4Leucovorin 4dabrafenib 3Fluorouracil 33-Iodobenzylguanidine 3trametinib 2selpercatinib 2lutetium Lu 177 dotatate 2avelumab 2alectinib 2PM 01183 2Oxaliplatin 2Irinotecan 2Fulvestrant 2Drug Therapy 2Doxorubicin 2Cisplatin 2trifluridine tipiracil drug combination 1tipifarnib 1telotristat ethyl 1surufatinib 1somapacitan 1ribociclib 1repotrectinib 1pralsetinib 1pentetreotide 1pegfilgrastim 1pasireotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × Referral and Consultation × Endocrine × Clear all
NCT06908629 2025-08-26

Addressing Social Determinants of Health Among Metro Detroit Cancer Survivors

Barbara Ann Karmanos Cancer Institute

Phase NA Recruiting
120 enrolled
EndocrineGastrointestinalNETPlasma cell

Gastrointestinal Neoplasms, Multiple Myeloma, Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡